Owings Mills, Maryland Clinical Trials

A listing of Owings Mills, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Chesapeake Urology Associates
 (9.3 away) Contact site
  • 0 views
  • 23 Nov, 2020
  • +348 other locations
Muscadine Plus (MPX) In Men With Prostate Cancer

This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease in PSA slope following treatment compared to men that do not supplement with MPX.

metastasis
prostate tumor
testosterone
prostate specific antigen
cancer
Chesapeake Urology Research Associates
 (9.3 away) Contact site
  • 22 views
  • 20 Jul, 2020
  • +13 other locations
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue …

Chesapeake Urology Associates
 (9.3 away) Contact site
  • 0 views
  • 23 Nov, 2020
  • +224 other locations
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (< 50 nanograms/deciliter [ng/dL]) in participants with androgen-sensitive advanced prostate cancer.

metastasis
testosterone
serum testosterone
adenocarcinoma
cryotherapy
Baltimore
 (7.6 away) Contact site
  • 1590 views
  • 04 Nov, 2020
  • +351 other locations
Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to …

tumor cells
antiandrogen therapy
cancer vaccine
androgens
external beam radiation therapy
Chesapeake Urology Research Associates
 (9.3 away) Contact site
  • 1420 views
  • 05 Nov, 2020
  • +76 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP plus placebo.

Chesapeake Urology Research Associates
 (9.3 away) Contact site
  • 498 views
  • 15 Oct, 2020
  • +479 other locations
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.

adenocarcinoma
adenocarcinoma of prostate
prostatectomy
Chesapeake Urology Research Associates
 (7.6 away) Contact site
  • 0 views
  • 24 Nov, 2020
  • +31 other locations
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants with mCRPC who have failed to respond to either abiraterone acetate or enzalutamide (but not both) and to chemotherapy. …

orchiectomy
metastatic castration-resistant prostate cancer
androgen suppression
adenocarcinoma of prostate
bisphosphonate
Chesapeake Urology Research Associates ( Site 0076)
 (9.3 away) Contact site
  • 394 views
  • 25 Nov, 2020
  • +201 other locations
Study to Evaluate the Efficacy Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.

nocturia
alpha blocker
benign prostatic hypertrophy
vibegron
cancer
Chesapeake Urology Research Associates
 (9.3 away) Contact site
  • 959 views
  • 24 Aug, 2020
  • +146 other locations
Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.

adenocarcinoma
prostatectomy
prostate specific antigen
adenocarcinoma of prostate
Chesapeake Urology Research Associates
 (7.6 away) Contact site
  • 20 views
  • 23 Nov, 2020
  • +28 other locations